Former TapImmune Chairman & CEO to head up company’s pharmaceutical and OTC trial exploration and partnership efforts in researching efficacy of CBD treatments
Today CBD Brands, a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (CBD) via a multitude of convenient products, announced that it has appointed Dr. Glynn Wilson to its Board of Directors. Dr. Wilson, who previously served as the Chairman & CEO of TapImmune, Inc. prior to its merger with Marker Therapeutics, Inc., will draw from his more than 20 years of experience in the pharmaceutical industry to help expand clinical trials and research into the effectiveness of cannabidiol in the treatment of cancer as well as in combination therapy with existing cancer treatments on the market.
“This represents a huge opportunity to provide new medical and therapeutic products for patients,” said Wilson. “Studies have already shown that CBD may be successful in the treatment of common ailments like anxiety and joint pain, and–perhaps more notably–pre-clinical trials have shown significant promise for its use in the treatment of certain cancers. From my recent work in immunotherapy my goal has been to examine new ways of treating unmet medical needs and in to take exciting new approaches through clinical trials, so I am delighted to join the team at CBD Brands to be part of the emerging field of CBD and cannabinoid research and clinical evaluation.”
Dr. Wilson brings an extensive background in corporate and product management in the pharmaceutical and biotech industries to his role with CBD Brands. He formerly served as Head of Drug Delivery at SmithKline Beecham Pharmaceuticals, Research Area Head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and most recently as Chairman & CEO of TapImmune where he developed the clinical pipeline and up-listed the Company to the Nasdaq National Market. Through his expertise in taking lead product concepts and technologies from ideation to commercialization, his background is perfectly suited to help CBD Brands explore the targeted, transdermal absorption of CBD via the brand’s initial products CaniSun and CaniSkin.
“Studies have already shown that the consistent application of CBD to the skin can help provide significant targeted pain relief and inflammation relief in arthritic joints,” said Wilson. “That alone is immensely exciting, but to pair that potential with the dedication CBD Brands has to develop easy-to-use pharmaceutical quality CBD products provides many exciting opportunities.”
“Dr. Wilson’s background in the pharmaceutical industry is beyond reproach,” Brian John, the CEO of CBD Brands, said about Dr. Wilson’s appointment to the board. “We’re fortunate to have his leadership as we continue to explore the relatively uncharted waters and possibilities for therapeutic applications of CBD. We know his guidance can help us in our pursuit to create life-changing products.”
Dr. Wilson has a Ph.D. in Biochemistry and has conducted medical research at The Rockefeller University in New York. His initial responsibilities with the company will be in strategizing a roadmap for success in the rapidly growing hemp-derived CBD market, which is expect to exceed $20 billion within three years.
About CBD Brands, Inc.
CBD Brands is a leading a cutting-edge wellness brand dedicated to exploring the multiple therapeutic and medical uses of cannabidiol (CBD) via a collection of convenient products and services. It is dedicated to advancing research into the multitude of medical and therapeutic uses of CBD for treatment of common ailments like cancer, arthritis, anxiety, and insomnia, among others. The Company was formed in 2018 and is headquartered in Jupiter, Florida. For investor relations, please visit CBDbrands.net, or follow the brand on Facebook and Twitter.
Safe Harbor Statement
To the extent any statements contained in this presentation of CBD Brands, Inc. (the “Company”) contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,” “projected” and other words or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.
CBD Brands, Inc. Company Contact
Main Office: 561.406.2469